2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.29 Alder

PP01.29 Alder - Poster

Pdf Summary

The study focused on investigating the impact of STK11 and CDKN2A alterations in non-small cell lung cancer (NSCLC) patients with brain metastases (BrMs). The research analyzed 191 patients with NSCLC and BrMs, categorizing them based on genetic alterations in STK11 and CDKN2A. The results indicated that patients with these alterations had a significant impact on overall survival (OS) and progression-free survival (PFS) compared to those without the alterations. Both STK11 and CDKN2A subgroups were more prevalent in male and black patients. Patients with STK11 or CDKN2A alterations had shorter OS from initial metastatic diagnosis and initial BrMs diagnosis, as well as reduced PFS from the date of the first treatment post-Genant360 testing. The majority of patients received central nervous system radiation therapy, with stereotactic radiosurgery being the most common treatment method. The study suggests the need for further research to explore the potential of STK11 and CDKN2A alterations as predictive biomarkers for the development of BrMs and to determine optimal treatment strategies. Additional studies are required to better understand the clinical implications of these genetic alterations in NSCLC patients with brain metastases.

Keywords

STK11

CDKN2A

non-small cell lung cancer

NSCLC

brain metastases

genetic alterations

overall survival

progression-free survival

male patients

black patients